Antitumor activity
Tumor
TUMOR
All patients were subjected to efficacy analysis. Fifteen patients (57.7%) in the efficacy evaluable population had smaller target lesions than those at baseline. Among these 15 patients, 10 achieved an OR according to RESIST1.1.(Tumor responses as assessed by the investigators or independent reviewers.
Survival outcomes of the patients with RM-NPC. Kaplan-Meier plots showing progression-free survival 
